MORPHOSYS AG
MORPHOSYS AG (DELISTED)
Action · DE0006632003 · 663200 (XETR)
Aperçu Indicateurs financiers
Pas de cours
n/a

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
- - - - 0,00 % 0,52 % -39,39 %

Profil de l'entreprise pour MORPHOSYS AG Action

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Fonds investis

Les fonds suivants ont investi dans : MORPHOSYS AG investi :

Fonds
iShares TecDAX® UCITS ETF (DE) EUR (Dist)
Vol. en millions
3,72
Part (%)
1,18 %
Fonds
iShares TecDAX® UCITS ETF (DE) EUR (Acc)
Vol. en millions
12.878,53
Part (%)
1,18 %
Fonds
iShares EURO STOXX Small UCITS ETF EUR (Dist)
Vol. en millions
6.502,84
Part (%)
0,51 %
Fonds
iShares MDAX® UCITS ETF (DE) EUR (Dist)
Vol. en millions
12,61
Part (%)
0,46 %
Fonds
iShares MSCI EMU Small Cap UCITS ETF EUR (Acc)
Vol. en millions
2.364,24
Part (%)
0,28 %

Données de l'entreprise

Nom MORPHOSYS AG
Société MorphoSys AG
Site web https://www.morphosys.com
Marché d'origine XETR XETRA
WKN 663200
ISIN DE0006632003
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Mr. Arkadius Pichota M.B.A., Ph.D.
Capitalisation boursière 3 Mrd.
Pays Allemagne
Devise EUR
Employés 0,5 T
Adresse Semmelweisstrasse 7, 82152 Planegg
Date d'introduction en bourse 1999-03-10

Symboles boursiers

Nom Symbole
Frankfurt MOR.F
XETRA MOR.DE

Autres actions

Les investisseurs qui détiennent MORPHOSYS AG ont également les actions suivantes dans leur portefeuille :
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Action
AMAZON.CO INC
AMAZON.CO INC Action
BAYER AG
BAYER AG Action
GEELY AUTO. S  HD-,02
GEELY AUTO. S HD-,02 Action
INFINEON TECHNOLOGIESLOGIES AG
INFINEON TECHNOLOGIESLOGIES AG Action
ISHARES MSCI EMERGING MARKETS
ISHARES MSCI EMERGING MARKETS ETF
META PLATFORMS INC
META PLATFORMS INC Action
MICROSOFT CORP
MICROSOFT CORP Action
PAYPAL INC
PAYPAL INC Action
POWERTAP HYDRO.CAP.CORP
POWERTAP HYDRO.CAP.CORP Action
SAP SE
SAP SE Action
TESLA INC
TESLA INC Action
ULSTER BK IRELAND 98/UND.
ULSTER BK IRELAND 98/UND. Obligation
WALT DISNEY INC
WALT DISNEY INC Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025